Sunday, November 24, 2019 3:28:59 PM
It's my belief that if the SOC for a given cancer cured 95% of patients with the cancer there would still be research on how to cure the 5%. Certainly it wouldn't be heavily funded, but people would still be working on it. Frankly, the more we're able to learn about cancer and other diseases, the more personalized treatment will become. In the above example, the ideal treatment would identify the 5% who didn't see benefits from the treatment that cured 95%, and treat them in a different manner.
It's now been nearly 6 years since my diagnosis with PH+ ALL. Before my treatment began with chemo it was halted for a few hours. Why? Because the final results of the testing they were doing showed that their initial evaluation of my disease as AML was wrong, it had taken roughly a week for the final results to come in. The course of treatment was quite different for the 2 different diseases.
I believe our technology is rapidly improving. The testing that took over a week a half dozen years ago will probably be done in a few hours in the future. This may not be the case if cultures must be grown before a determination can be made. During my treatment on two occasions I had catheter infections, each case took several days to determine the precise infection. In both cases, the antibiotic they initiated treatment with helped, but something with greater efficacy was used when the specifics of the infection were known.
Gary
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM